Conditions: Leukemia, Myelomonocytic, Acute
Keywords: Leukemia, Myelomonocytic, Acute Erlotinib
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 11
Healthy volunteers: no

Brief summary:
This research study is looking for patients with newly diagnosed acute myeloid leukemia (AML), AML that has returned (relapsed), or it has not responded adequately to previous treatments. Treating certain patients with chemotherapy may not be to their benefit or may cause more harm than benefit. The purpose of this study is to find out what effects (good and bad) erlotinib has on patients and their AML.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Erlotinib
Intervention descriptions: intervention 1: Erlotinib will be administered orally at 150 mg once a day, continuously. Each cycle will be 28 days and there will be no break between the cycles.

Protocol document: